Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA – Get Rating) have received a consensus rating of “Hold” from the seven research firms that are presently covering the firm, Marketbeat reports. Six investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $1.75.
AKBA has been the subject of several research reports. StockNews.com raised shares of Akebia Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, March 9th. HC Wainwright reissued a “neutral” rating and set a $1.25 price objective on shares of Akebia Therapeutics in a research report on Friday, March 10th.
Insider Buying and Selling
In related news, CEO John P. Butler sold 91,868 shares of the company’s stock in a transaction dated Wednesday, March 1st. The shares were sold at an average price of $0.88, for a total transaction of $80,843.84. Following the transaction, the chief executive officer now owns 1,568,872 shares in the company, valued at approximately $1,380,607.36. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Over the last quarter, insiders have sold 132,524 shares of company stock valued at $116,621. 3.68% of the stock is owned by company insiders.
Institutional Investors Weigh In On Akebia Therapeutics
Akebia Therapeutics Trading Down 1.7 %
AKBA opened at $0.67 on Thursday. The firm has a market cap of $123.72 million, a P/E ratio of -1.29 and a beta of 0.84. Akebia Therapeutics has a 12 month low of $0.24 and a 12 month high of $2.60. The stock has a 50-day moving average of $0.80 and a 200 day moving average of $0.50.
Akebia Therapeutics Company Profile
Akebia Therapeutics, Inc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat.
- Get a free copy of the StockNews.com research report on Akebia Therapeutics (AKBA)
- Meta Platforms: Efficiency Gains Momentum, Stock Accelerates
- Pfizer’s Latest Acquisition Strengthens the Case for PFE Stock
- SentinelOne: Reversal In-Play For Cybersecurity Stocks
- Is Sportradar Group A Growth Stock To Bet On In 2023?
- Strong Guidance says Boeing is Ready for Takeoff
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.